Note: Organic growth; Adj EBITDA and Adj EPS are non-GAAP financial measure. 6 IART Q4 2023 Earnings Presentation Note: Adj. EBITDA margin, and adj. EPS are non-GAAP financial measures. Codman Specialty Surgical Q4 Revenue Adj. EBITDA Margin 25.3% (230bps) vs. 2022 Q4 Revenue and adj. EPS within guidance range Tissue Technologies Q4 Revenue Revenues Q4'23 Q4 Growth Q4 Growth excl. Boston Organic1 $122.7M (8.0%) 6.9% 7.2% | --- | --- | --- | |----------------------|------------------------------------------- ...

News Release Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance Princeton, New Jersey, February 28, 2024 - Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Full-Year 2023 Business Highlights "In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products an ...

COMMISSION FILE NO. 000-26224 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q3 2023 Earnings Call October 25, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director of Investor Relations Jan De Witte - President and Chief Executive Officer Lea Daniels Knight - Chief Financial Officer Conference Call Participants Young Li - Jefferies Vik Chopra - Wells Fargo Robbie Marcus - J.P. Morgan Ryan Zimmerman - BTIG Craig Bijou - Bank of America Securities Richard Newitter - Truist Securities Steven Lichtman - Oppenheimer and ...

Third Quarter 2023 Net Debt Reconciliation Revenue $1.541B-$1.547B | --- | --- | --- | |--------------|-------------------------------------------------------|---------------------| | Neurosurgery | Q3 2023 Growth and Performance Drivers2 \nInstruments | International | | 8.0% | 5.0% | Double-Digit growth | Private Label 22.9% Wound Reconstruction 77.1% IART Q3 2023 Earnings Presentation Note: Organic growth, adj. gross margin, adj. EBITDA margin and adj. EPS are non-GAAP financial measures. $193.1 IART Q3 ...

Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted gross profit, adjusted gross margin, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR O ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President and Chief Executive Officer Lea Knight - Executive Vice President & Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Rohan Patel - JP Morgan Young Li - Jefferies David Turkaly - JMP Securities Vik Chopra - Wells Fargo Samuel Brodovsky - Truist Securities Ryan Zimmerman ...

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR ...

Q1 2023 EARNINGS PRESENTATION APRIL 26, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may," "could," "would," ...